Assertio (ASRT)
(Delayed Data from NSDQ)
$1.54 USD
-0.12 (-7.23%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $1.55 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.54 USD
-0.12 (-7.23%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $1.55 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Assertio (ASRT) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Top Ranked Value Stocks to Buy for September 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, September 9th
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Assertio Therapeutics Enters Oversold Territory
by Zacks Equity Research
Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
ASRT vs. PCRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Assertio (ASRT) Q2 Earnings Beat Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT or AMRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. AMRX: Which Stock Is the Better Value Option?
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza
by Zacks Equity Research
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
Savara Plunges on Failure of Late-Stage Study on Molgradex
by Zacks Equity Research
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
BioCryst Down Despite Hereditary Angioedema Study Meets Goal
by Zacks Equity Research
BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.
ASSERTIO THERAPEUTICS Enters Oversold Territory
by Zacks Equity Research
ASSERTIO THERAPEUTICS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ASRT) Outperforming Other Medical Stocks This Year?
Assertio (ASRT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 27.78% and 4.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
by Zacks Equity Research
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
Will Assertio Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Assertio Therapeutics.
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
New Strong Buy Stocks for March 13th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ASRT or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 22nd: